Compare AGCO Corporation (AGCO) vs CVS Health Corp (CVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AGCO Corporation vs CVS Health Corp — how do they compare? AGCO Corporation trades at $102.25 (market cap $7.06B), while CVS Health Corp trades at $93.65 (market cap $122.36B). The key difference: CVS Health Corp is far larger — about 17.3× AGCO Corporation's market cap, and CVS Health Corp pays the higher dividend (2.78%). Which is the better fit depends on your goals.
| AGCO | CVS | |
|---|---|---|
Market Cap | $7.06B | $122.36B |
Sector | Industrials | Health |
52-Week High | $140.49 | $110.60 |
52-Week Low | $100.14 | $65.51 |
Enterprise Value | $9.33B | $184.71B |
Dividend Yield | 1.19% | 2.78% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AGCO trades at $102.83, up 1.18% on the day, but faces bearish technical signals with the stock trading near key support at $102. The agricultural equipment manufacturer reported mixed Q2 2026 results, missing earnings estimates but maintaining a solid balance sheet with $612 million in cash. Recent leadership changes and multiple securities investigations create uncertainty, though the company's valuation remains attractive with a P/E of 14.22 and P/S of 0.73.
While AGCO's fundamentals show resilience with positive cash flow and reasonable valuation, near-term headwinds from weaker industry conditions and legal scrutiny present significant risks. The 37.9% analyst buy rating and $124.63 price target suggest potential upside, but investors should weigh the bearish technical outlook against the company's long-term positioning in precision agriculture.
CVS Health trades at $95.70, down 0.54% on the day, with a bearish technical signal and key support at $95. The company reported strong Q2 2026 earnings, beating estimates with EPS of $2.58 versus $1.87 expected, and raised its full-year guidance. Revenue growth remains robust, reaching $402.07 billion in 2025, though net income margin compressed to 1.18%. Analyst sentiment is overwhelmingly positive with a consensus price target of $115.00.
The outlook for CVS is cautiously optimistic, driven by operational improvements in its Aetna segment and raised cash flow guidance. Investment opportunities include potential upside to the consensus target, but risks involve margin pressures, regulatory changes impacting pharmacy benefits in 2027, and high debt levels. The stock's current valuation at a P/E of 25.25 may limit near-term gains if earnings growth slows.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AGCO Corporation
Agco is a global manufacturer of agricultural equipment. The company has five principal brands: Fendt, Massey Ferguson, Challenger, Valtra, and GSI. Unlike its competitors, Agco's product line extends beyond self-propelled equipment and implements by offering grain handling systems and livestock management solutions. Its products are available through a global dealer network, which includes over 3,200 dealer and distribution locations. Additionally, Agco offers both retail and wholesale financing to customers through its joint venture with Rabobank, a European food and agriculture focused bank.
Read more on AGCO →About CVS Health Corp
Following its acquisition of Aetna in late 2018, CVS Health now provides an even more integrated healthcare-services offering for its members. Legacy CVS combined both the largest pharmacy benefit manager, processing over 2 billion adjusted claims annually, and a sizable pharmacy operation, including nearly 10,000 retail pharmacy locations primarily in the U.S. Adding a managed-care organization with 24 million medical members gives the company a strong position in the insurance industry and should help CVS better control overall healthcare costs for its clients.
Read more on CVS →
